Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 05.31
    2013

    Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

  • 05.28
    2013

    Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders

  • 05.21
    2013

    Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

  • 05.02
    2013

    Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

  • 04.30
    2013

    Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

  • 04.30
    2013

    Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence

  • 04.24
    2013

    Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441

  • 04.22
    2013

    Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

  • 04.18
    2013

    Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

  • 03.21
    2013

    Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics